Mantiini 10 mg (Memantine Hydrochloride)

Adult dose

This medication is administered orally once daily at the same time each day. If needed, it can be given twice daily. The maximum daily dose increase is 20 mg, with an incremental increase of 5 mg per week for the first three weeks. First week (Day 1–7): Administer 5 mg daily Second week (Day 8–14): Administer 10 mg daily Third week (Day 15–21): Administer 15 mg daily From the fourth week onwards, administer 20 mg daily.

This medication should not be used by patients with a known hypersensitivity to its components or with severe liver or kidney impairment. It should be used with caution in patients with epilepsy or those with a history of seizures, or in patients who have a predisposition to seizures. Additionally, it should not be co-administered with NMDA antagonists such as amantadine, ketamine, or dextromethorphan, as this may increase the risk of adverse effects. Patients with factors that can change urine acidity (pH), such as sudden changes in diet or specific urinary tract infections, should be closely monitored. Due to insufficient clinical data, it should be used cautiously in patients with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension. While taking this medication, watch for symptoms such as dizziness, headache, constipation, drowsiness, and hypertension, as these side effects may occur. Central nervous system adverse reactions such as psychiatric confusion, hallucinations, and psychotic responses have also been reported, so if any abnormal symptoms appear, consult a healthcare professional immediately. This medication can interact with other drugs, so if the patient is taking NMDA antagonists, dopamine agonists, anticholinergic drugs, antipsychotic medications, skeletal muscle relaxants, or anticoagulants, they must consult with a doctor or pharmacist. Women who are pregnant or may become pregnant should carefully consider the potential risk to the fetus before using this medication, and nursing mothers are advised to discontinue breastfeeding as this medication may be passed into breast milk. The safety and efficacy of this medication in children and adolescents under 18 years of age have not been established, so it is not recommended for use in this age group. In case of overdose, symptoms such as confusion, drowsiness, dizziness, agitation, hallucinations, gait disturbances, vomiting, and diarrhea may occur. In such cases, general treatment such as gastric lavage or activated charcoal should be conducted as there is no specific antidote. Care should be taken while driving or operating machinery during this medication; especially in Alzheimer's disease patients whose reaction times may be slowed. Finally, this medication should be stored out of the reach of children, and transferring it to another container can compromise the quality of the medication, so caution is advised.

Serious side effects

• Seizures
• hallucinations
• psychotic responses
• heart failure
• venous thrombosis/thromboembolism
• dyspnea
• pancreatitis
• hepatitis

Mild side effects

• Dizziness
• headache
• constipation
• drowsiness
• hypertension
• confusion
• hallucinations
• psychotic responses
• balance disorders
• gait abnormalities

This medication should be stored in a tightly sealed container to prevent air and moisture from entering. It is best kept at room temperature between 1°C and 30°C, avoiding very hot or cold locations.

Appearance

Pale yellow to yellow oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle